Guevara-Montero MA, Pérez‑Ong J, Vera-Delgado J, Saldierna-Jiménez E

Language: Spanish
References: 10
Page: 81-84
PDF size: 203.04 Kb.

ABSTRACT

Introduction: A case of an 82-year-old male is reported, who comes to our center presenting an essential thrombocytosis, with platelet levels › 2,000 x 103/µL. The patient was treated by therapeutic plateletapheresis performed with a donation kit. At the end of the last procedure, he presented improvement. Objective: The parameters used in apheresis equipment are described. Material and methods: An Amicus^® apheresis machine, a platelet donation kit, was used. Results: It was necessary to modify the parameters of the apheresis machine to enable it and thus achieve the procedure, since it was not designed to perform therapeutic plateletapheresis procedures, because it does not allow the introduction of pathological parameters. Two series of 6 procedures were performed, one every 24 hours. At the end of each series there was a decrease in platelet count and decrease in its symptomatology. Conclusions: After the series of procedures, clinical improvement (decrease in associated symptoms) and laboratory (a return in platelet numbers to normal ranges) were presented. This treatment should be considered as a good alternative in sites that do not have specific equipment for the performance of therapeutic plateletapheresis.

REFERENCES

1. American Cancer Society. ¿Qué causa la leucemia mieloide crónica? [Internet]. [citado el 26 de julio de 2019]. Disponible en: https://www.cancer.org/es/cancer/leucemia-mieloide-cronica/causas-riesgos-prevencion/que-lo-causa.html

2. Castro Ríos M, Heller P, Kornblihtt L, Larripa I, Marta R, Martín C et al. Guía Diagnóstica Terapéutica. Trombocitemia esencial. Sociedad Argentina de Hematología; 2010.

3. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue: therapeutic apheresis-guidelines 2016. J Clin Apheresis. 2016; 31 (3): 149-338.

4. Hall JE. Guyton y Hall. Tratado de fisiología médica. 13ª ed. Madrid: Elsevier; 2017.

5. McPherson RA, Pincus MR. Henry’s clinical diagnosis and management by laboratory methods. Philadelphia: Saunders Elsevier; 1823.

6. Información sobre la trombocitemia esencial [Internet]. [citado el 30 de septiembre de 2019]. Disponible en: https://www.lls.org/sites/default/files/file_assets/sp_essentialprimarythrombocythemia.pdf

7. Ángel Mejía G, Ángel Ramelli M. Interpretación clínica del laboratorio. 7ª ed. Bogotá: Editorial Médica Panamericana; 2006.

8. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016; 31 (3): 149-162.

9. Trombocitosis [Internet]. [citado el 30 de septiembre de 2019]. Disponible en: https://www.medigraphic.com/pdfs/medsur/ms-2013/ms134j.pdf

10. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.